Biotech Values

[DewDiligence]

Abbvie would have no problem becoming hostile.

A hostile buyout might not be advantageous for ABBV if it caused ENTA’s drug-discovery scientists to jump ship. Moreover, there may be impediments on ABBV’s standing to pursue a hostile deal as a consequence of the equity agreement between ABT an ENTA in 2006.